JPMorgan Chase & Co. Purchases 761,008 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

JPMorgan Chase & Co. boosted its holdings in Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 145.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,284,708 shares of the company's stock after purchasing an additional 761,008 shares during the period. JPMorgan Chase & Co. owned approximately 0.48% of Autolus Therapeutics worth $4,663,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in AUTL. Wellington Management Group LLP increased its stake in Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company's stock worth $87,919,000 after purchasing an additional 6,330,392 shares during the period. State Street Corp increased its stake in shares of Autolus Therapeutics by 1.7% in the third quarter. State Street Corp now owns 606,544 shares of the company's stock worth $2,202,000 after buying an additional 10,401 shares during the period. HighVista Strategies LLC raised its holdings in Autolus Therapeutics by 2.7% during the 3rd quarter. HighVista Strategies LLC now owns 533,024 shares of the company's stock valued at $1,935,000 after buying an additional 14,204 shares during the last quarter. Erste Asset Management GmbH bought a new stake in Autolus Therapeutics during the 3rd quarter valued at $708,000. Finally, Bellevue Group AG boosted its position in Autolus Therapeutics by 27.7% during the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company's stock valued at $151,000 after buying an additional 9,000 shares during the period. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $2.22 on Friday. Autolus Therapeutics plc has a 1 year low of $2.07 and a 1 year high of $7.37. The stock has a market capitalization of $590.72 million, a P/E ratio of -1.83 and a beta of 2.05. The company's 50-day moving average is $2.70 and its 200 day moving average is $3.56.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the company earned ($0.26) earnings per share. Research analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Redburn Atlantic raised Autolus Therapeutics from a "neutral" rating to a "buy" rating and set a $13.00 price target for the company in a research report on Friday, November 15th. Finally, The Goldman Sachs Group upgraded Autolus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $10.40.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.